Results 351 to 360 of about 425,993 (391)

Outcomes 10 Years After Implementing an Emergency Department Opt-out Bloodborne Virus Screening Program. [PDF]

Open Forum Infect Dis
Townsend L, Herraghty F, Brennan S, Grant C, Wang W, Moriarty A, Lynagh Y, Clancy L, Power A, Crowley B, Norris S, Shields D, Bergin C.   +12 more
europepmc   +1 more source

Reducing blood component wastage through targeted interventions: A four‐year retrospective study at a Saudi tertiary hospital

Transfusion Medicine, EarlyView.
Abstract Background Blood transfusion services are vital to healthcare; however, blood component wastage remains a persistent challenge for transfusion facilities, impacting resource efficiency and patient care. In this four‐year retrospective before‐and‐after study, we investigated blood component wastage at a tertiary hospital in Saudi Arabia to ...
Wajnat A. Tounsi, Osama A. Alzahrani, Ahmed G. Bukhari, Raed M. Garout, Raed I. Felimban, Ruqaia H. Al‐Musallam, Waleed M. Bawazir, Hadeel Al Sadoun, Majed R. Algarni, Walaa H. AlAmoudi, Nawaf M. Alomayri, Mohammed A. Labban, Sara S. Alghamdi, Nora Y. Hakami   +13 more
wiley   +1 more source

Cure of chronic hepatitis C virus infection after DAA treatment only partially restores the functional capacity of exhausted T cell subsets: a systematic review. [PDF]

Front Immunol
Apol ÁD, Sølund C, Vinten C, Underwood AP, Bukh J, Weis N.   +5 more
europepmc   +1 more source

Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024. [PDF]

J Viral Hepat
Luong CL, Ellett LK, Pratt N, Staff K, Janetzki J.   +4 more
europepmc   +1 more source

From Guidelines to Real-Time Conversation: Expert-Validated Retrieval-Augmented and Fine-Tuned GPT-4 for Hepatitis C Management. [PDF]

Liver Int
Giuffrè M, Pugliese N, Kresevic S, Ajcevic M, Negro F, Puoti M, Forns X, Pawlotsky JM, Shung DL, Aghemo A.   +9 more
europepmc   +1 more source

The diagnostic value of decreased levels of inflammatory markers for the state of hepatitis C virus (HCV) infection. [PDF]

PLoS One
Han L, Bi L, Li X.
europepmc   +1 more source

Assessment of hepatitis C virus permissiveness in iteratively genetically humanized mice. [PDF]

J Virol
Schwoerer MP, Carver S, Cafiero TR, Joyce B, Berggren KA, Suzuki S, Heller B, O'Connell AK, Gertje HP, Crossland NA, Posfai E, Ploss A.   +11 more
europepmc   +1 more source

Integrating hepatitis B virus, hepatitis C virus and human immunodeficiency virus screening for migrants from endemic countries into travel-related and sexual health care in Amsterdam, the Netherlands. [PDF]

Front Public Health
Generaal E, Bachour Y, Klijzing S, Cornelissen A, Toering R, Hoornenborg E, Op de Coul E, Hamdiui N, Meiberg A, Siedenburg E, Prins M.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HCV and Autoimmunity

Current Pharmaceutical Design, 2008
Hepatitis C virus (HCV) infection is characterized by a number of autoreactive manifestations, such as autoantibody production, cryoglobulinemia and thyroid disorders. We will analyse critically the mechanisms invoked, and partially documented, to explain such manifestations arising in genetically predisposed individuals exposed to HCV.
FERRI, SILVIA, MURATORI, LUIGI, LENZI, MARCO, GRANITO, ALESSANDRO, BIANCHI, FRANCESCO BIANCO, Vergani D.   +5 more
openaire   +3 more sources